Hypobetalipoproteinemia and abetalipoproteinemia

Current Opinion in Lipidology

Volumn 25, Issue 3, 2014, Pages 161-168

  Welty, Francine K ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Abetalipoproteinemia; angiopoietin like 3 protein; combined hypolipidemia; hypobetalipoproteinemia; proprotein convertase subtilisin kexin type 9

Indexed keywords

ENZYME INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANGIOPOIETIN; ANGPTL3 PROTEIN, HUMAN; APOLIPOPROTEIN B; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ABETALIPOPROTEINEMIA; ANGPTL3 GENE; CORONARY ARTERY DISEASE; FAMILIAL DISEASE; FATTY LIVER; GENE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HYPOBETALIPOPROTEINEMIA; HYPOLIPEMIA; INSULIN SENSITIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PCSK9 GENE; PRIORITY JOURNAL; REVIEW; ACTIVE TRANSPORT; BLOOD; FAMILIAL HYPOBETALIPOPROTEINEMIA; GENETICS; LIPID METABOLISM; LIVER TUMOR; METABOLISM; MUTATION;

ABETALIPOPROTEINEMIA; ANGIOPOIETINS; APOLIPOPROTEINS B; BIOLOGICAL TRANSPORT, ACTIVE; CARCINOMA, HEPATOCELLULAR; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER NEOPLASMS; MUTATION; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 84900524103     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000072     Document Type: Review

References (37)

1. Havel RJ, Kane JP. Introduction: Structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, 7th ed. New York, NY: McGraw-Hill; 1995. pp. 1841-1851.
2. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990; 82:1574-1594.
3. Chen SH, Habib G, Yang CY, et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 1987; 238:363-366.
4. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, et al. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000; 20:663-697.
5. Weisgraber KH, Rall SC Jr. Human apolipoprotein B-100 heparin-binding sites. J Biol Chem 1987; 262:11097-11103.
6. Sehayek E, Lewin-Velvert U, Chajek-Shaul T, Eisenberg S. Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein. J Clin Invest 1991; 88:553-56 0.
7. Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol- anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007 ; 5:279-291.
8. Linton MF, Farese RV Jr, Young SG. Familial hypobetalipoproteinemia. J Lipid Res 1993; 34:521-541.
9. Burnett JR,Bell DA,Hooper AJ,Hegel RA Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB). Eur J Hum Genet, 2012, 20, e1-e3.
10. Welty FK, Hubl ST, Pierotti VR, Young SG. A truncated species of apolip oprotein B (B67) in a kindred with familial hypobetalipoproteinemia. J Clin Invest 1991; 87:1748-1754.
11. Welty FK, Ordovas J, Schaefer EJ, et al. Identification and molecular analysis of t wo apoB gene mutations causing low plasma cholesterol levels. Circulation 1995; 92:2036-2040.
12. Welty FK, Lichtenstein AH, Barrett PH, et al. Decreased production and increased catabolism of ap olipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler Thromb Vasc Biol 1997; 17: 881-888.
13. Welty FK, Lichtenstein AH, Barrett PH, et al. Production of apolipoprotein B-67 in apolipoprotein B-67/B-100 heterozygotes: Technical problems associated with leucine contamination in stable isotope studies. J Lipid Res 1997; 38:1535-1543.
14. Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 1999; 19:2714-2721.
15. Aguilar-Salinas CA, Barrett PH, Parhofer KG, et al. Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. Arterioscler Thromb Vasc Biol 1995; 15:71-80.
16. Parhofer KG, Barrett PH, Aguilar-Salinas. Schonfeld G. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: In vivo studies in human apoB89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. J Lipid Res 1996; 37:844-852.
17. Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: Roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res 2004; 45:941-947.
18. Schonfeld G, Patterson BW, Yablonskiy DA, et al. Fatty liver in familial hypobetalipoproteinemia: Triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 2003; 44:470-478.
19. Della Corte C, Fintini D, Giordano U, et al. Fatty liver and insulin resistance in children with hypobetalipoproteinemia: The importance of aetiology. Clin Endocrinol 2013; 79:49-54.
20. Visser ME, Lammers NM, Nederveen AJ, et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia 2011; 54:2113-2121.
21. Kotronen A, Vehkavaara S, Seppala-Lindroos A, et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 2007; 293:E1709-E1715.
22. Lonardo A, Lombardini S, S caglioni F, et al. Hepatic steatosis and insulin resistance: Does etiology make a difference J Hepatol 2006; 44:190-196.
23. Tarugi P, Lonardo A. Heterozygous familial hypobetalipoproteinemia associated with fatty liver. Am J Gastroenterol 1997; 92:1400-1402.
24. Bonnefont-Rousselot D, Condat B, Sassolas A, et al. Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B. Eur J Gastroenterol Hepatol 2009; 21:104-108.
25. Lonardo A, Tarugi P, Ballarini G, Bagni A. Familial heterozygous hypobetalipoproteinemia, extrahepa tic primary malignancy, and hepatocellular carcinoma. Dig Dis Sc 1998; 43:2489-2492.
26. Cefalu AB, Pirruccello JP, Noto D, et al. A novel apoB mutation identified by exome sequencing cosegregate s with steatosis, liver cancer and hypocholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33:2021-2025.
27. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
28. Hooper AJ, Burnett PC. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther 2013; 13:429-435. Excellent review summarizing the latest findings in clinical trials of PCSK9 inhibitors, including antibodies, gene silencing, and small peptides highlighting PCSK9 inhibition as an effective strategy for lowering plasma LDL-cholesterol.
29. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363: 2220-2227.
30. Pisciotta L, Favari E, Magnolo L, et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of function mutations of ANGPTL3. Circ Cardiovasc Genet 2012; 5:42-50.
31. Noto D,Cefalu AB,Valenti V,et al, Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler Thromb Vasc Biol, 2012, 32, 805-809. HDL-cholesterol levels may be use d to distinguish between ANGPTL3 and APOB mutations as causes of hypocholesterolemia.
32. Minicocci I, Montali A, Robciuc MR, et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: A clinical and b iochemical characterization. J Clin Endocrinol Metab 2012; 97:E1266-E1275.
33. Robciuc MR, Maranghi M, Lahikainen A, et al. Angptl3 deficiency is associated with increased insulin sensitivity, l ipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol 2013; 33:1706-1713.
34. Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: Abetalipoproteinaemia. Eur J Hum Genet 2012; 20:e1-e3.
35. Lee J and Hegele RA. Abetalipop roteinemia and homozygous hypobetalipoproteinemia: A framework for diagnosis and management. J Inherit Metab Dis published online: 28 Nov 2013.
36. Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
37. Calzada C, Vericel E, Colas R, et al. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: Evidence from patients with abetalipoproteinemia. FASEB J 2013; 27:2855-2861.